NDA 020213 · Bausch and Lomb
Miochol-E
Acetylcholine Chloride · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Jun 17, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Sep 22, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
150
18 Phase 3, 21 recruiting
FAERS reports
98
79 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 17, 2023.
INDICATIONS AND USAGE To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 22, 1993 Original approval · Type 3 - New Dosage Form
1 products under this application
- MIOCHOL-E · ACETYLCHOLINE CHLORIDE 20MG/VIAL · FOR SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetylcholine Chloride" as an intervention, any sponsor and status, largest first.
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
- A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyPivotal-lookingCompleted
FORUM Pharmaceuticals IncIndustry
NCT01714713 · 830 participants · Start Jun 2013 · Primary completion Oct 2015
Drug: EVP-6124 · For: Schizophrenia; Impaired Cognition
Sites: Little Rock, Arkansas; Anaheim, California; Bellflower, California · 128 sites in all
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyPivotal-lookingCompleted
FORUM Pharmaceuticals IncIndustry
NCT01716975 · 767 participants · Start Oct 2012 · Primary completion Feb 2016
Drug: EVP-6124; Placebo · For: Schizophrenia; Impaired Cognition
Sites: Phoenixville, Arizona; Little Rock, Arkansas; Cerritos, California · 106 sites in all
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyPivotal-lookingCompleted
FORUM Pharmaceuticals IncIndustry
NCT01714661 · 753 participants · Start Oct 2012 · Primary completion Dec 2015
Drug: EVP-6124; Placebo · For: Schizophrenia; Impaired Cognition
Sites: Tucson, Arizona; Anaheim, California; Bellflower, California · 94 sites in all
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07766655 · 705 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 2027
Drug: AXS-05 (dextromethorphan-bupropion); Bupropion and 1 more · For: Smoking Cessation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Lemon Grove, California · 28 sites in all
- Safety and Efficacy of MT-4666Pivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01764243 · 450 participants · Start Nov 2012 · Primary completion Jun 2015
Drug: MT-4666; Placebo · For: Alzheimer's Disease
Sites: Kanto, Japan
D. Walter WrayAcademic, hospital or other
NCT02966665 · 420 participants (planned) · Start Sep 2008 · Primary completion Aug 2030
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate; BQ-123 and 3 more · For: Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure and 1 more
Sites: Salt Lake City, Utah
- Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
FORUM Pharmaceuticals IncIndustry
NCT01073228 · 409 participants · Start Apr 2010 · Primary completion Nov 2011
Drug: EVP-6124; Placebo · For: Alzheimer's Disease; Central Nervous System Diseases; Cognition
Sites: Phoenix, Arizona; Chino, California; Costa Mesa, California · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- depression35
- cough34
- dyspnoea34
- rhinorrhoea34
- sinusitis34
- sleep disorder34
- sleep disorder due to a general medical condition34
- therapeutic product effect incomplete34
- anxiety33
- asthma33
- breast cancer33
- chest discomfort33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 17 |
| 2022 | 21 |
| 2023 | 11 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 11 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exercise training improves cutaneous microvascular endothelial function in post-surgical varicose vein patients.
Klonizakis M, Tew G, Michaels J, et al. · Microvasc Res 2009 · Randomized Controlled Trial
- Coronary endothelial dysfunction and impaired microcirculation response to atrial natriuretic peptide in hyperinsulinemia.
Ashikaga T, Nishizaki M, Fujii H, et al. · J Cardiovasc Pharmacol Ther 2008 · Controlled Clinical Trial
- Effect of acetylcholine on intraocular pressure following small-incision cataract surgery.
Wedrich A, Menapace R · Ophthalmologica 1992 · Clinical Trial, Randomized Controlled Trial
- Effects of exercise training and Mediterranean diet on vascular risk reduction in post-menopausal women.
Alkhatib A, Klonizakis M · Clin Hemorheol Microcirc 2014 · Randomized Controlled Trial
- Comparison of sub-Tenon's anaesthesia by different delivery techniques in cataract surgery.
Tokuda Y, Onda K, Yoshitomi F, et al. · Eye (Lond) 1999 · Clinical Trial, Randomized Controlled Trial
- Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis.
Sadik HY, Moore TL, Vail A, et al. · Rheumatology (Oxford) 2010 · Randomized Controlled Trial
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.